SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending after Elon Musk's recent purchase of $1 billion in TSLA stock, signaling confidence and sparking a short squeeze. The community is debating whether this is a long-term bullish signal or a short-term pump before a potential correction, especially given concerns about sales and expiring EV credits. Broader discussions include Tesla's potential beyond EVs, focusing on energy storage, robotics, and AI, while some remain skeptical, drawing comparisons to past market bubbles.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Asset Entities Inc.

Asset Entities Inc. is trending due to its recent merger with Strive and a new Bitcoin strategy, including a substantial buyback program, sparking community excitement about a potential short squeeze. Some traders are reporting difficulties trading the stock on certain platforms amidst the CUSIP change, leading to volatility and frustration, while others speculate on the impact of institutional ownership and potential news regarding Bitcoin purchases.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma ($ATYR) is trending downwards as the community anticipates the release of Phase 3 trial data for its lead drug, efzofitimod, with opinions split on its potential success. Discussions revolve around the trial's design, potential outcomes, and comparisons to past biotech events, highlighting the high stakes and binary nature of the stock's near-term future. Traders are actively debating hedging strategies and speculating on potential price movements based on different data scenarios.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its potential as the top meme coin on the Bitcoin network, emphasizing its fair launch and strong community. Discussions highlight the token's unique position within the Bitcoin ecosystem and the potential impact of increased visibility. Some community members also point to a partnership with $CBLO, which has been accumulating $DOG.X in its corporate treasury, as a key factor.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is trending due to a recent surge following positive trial results for its stroke therapy, with community members debating whether to hold for a potential FDA submission catalyst or take profits amidst concerns of manipulation and past reverse splits. The stock's low float is fueling discussions about a potential short squeeze, while some caution against a possible offering. The community is closely watching for news that could drive the price higher, as well as the company's next move.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to Needham's raised price target and overall excitement in the quantum computing sector, sparking discussions about its potential and possible acquisitions. Community members debate the company's valuation, long-term prospects, and potential to become the "next NVDA", while also discussing upcoming catalysts like the analyst day and potential government contracts. The stock's breakout and trading volume are also contributing to the increased attention.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as retail investors anticipate new peaks, with community members actively discussing potential price movements and key resistance levels. The stock is also gaining attention due to its participation in the White House's eVTOL pilot program and speculation around defense contracts. Community sentiment suggests anticipation for a potential squeeze, with some expressing frustration over the stock's performance compared to sector peers.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies behind the project's resilience and upcoming developments, including a Bifinance listing and airdrop. Community members highlight the project's organic growth, transparency, and active development team. Bullish sentiment is high, with many anticipating new ATHs and increased exposure for this Solana-based token.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors discuss the potential impact of a recent real-world tragedy, with some speculating it could drive increased traffic to the platform amid broader conversations around free speech. Community members are also weighing in on the company's fundamentals, potential catalysts like the upcoming wallet launch, and the proposed acquisition of Northern Data. Additionally, there's discussion around the high short interest and its potential to fuel a squeeze.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X Shares

Direxion Daily TSLA Bull 2X Shares

TSLL is trending as traders anticipate amplified moves from Tesla's earnings report. Community members are actively discussing potential breakouts and gamma squeezes, with many expressing bullish sentiment and targeting higher price levels. Elon Musk's recent increased stake in Tesla is also fueling optimism around the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.

Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains?

BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA

RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.

RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End

Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.

Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of Ultragenyx and Mereo BioPharma slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 (setrusumab) as initially planned, rather than ending it early as they had hoped.In after-hours trading on Wednesday, Mereo BioPharma dropped 38.8% to $1.80, while Ultragenyx fell 25.8% to $30.76.UX143 is a monoclonal antibody that inhibits sclerostin, a negative regulator of bone formation. It is being jointly developed by Ultragenyx and Mereo BioPharma.The Data Monitoring Committee (DMC) reviewed the Orbit study and found that the treatment’s safety profile appeared acceptable, recommending continuation to&nbsp;the final analysis.Final results from both the Orbit and Cosmic studies are expected to be released around the end of the year.The Orbit trial is testing UX143 in patients aged 5 to 25 with osteogenesis imperfecta, a condition characterized by brittle bones.&nbsp;Participants are receiving either the experimental treatment or a placebo, with the&nbsp;primary focus on&nbsp;the frequency of&nbsp;fractures.&nbsp;After the&nbsp;primary data is collected, all patients will move to open-label treatment.The Cosmic trial is running in parallel for children aged 2 to 7, comparing UX143 to standard bisphosphonate therapy.&nbsp;The study is also ongoing, with final results expected after patients&nbsp;have completed at least 18 months of treatment.On Stocktwits, retail sentiment for both&nbsp;<a href="https://stocktwits.com/symbol/MREO">Mereo BioPharma</a> and&nbsp;<a href="https://stocktwits.com/symbol/RARE">Ultragenyx</a> was tagged as ‘extremely bullish’ with ‘extremely high’ message volume.Some users&nbsp;suggested that the market was overreacting to the update from Mereo BioPharma and Ultragenyx, with one describing Mereo as a “good medium to long-term candidate” and another&nbsp;attributing the drop to a retail misunderstanding of standard clinical trial practices.<stembedurl>https://stocktwits.com/LogicalTrading/message/620417028</stembedurl><stembedurl>https://stocktwits.com/JCobb1/message/620403932</stembedurl>One comment noted that the final analysis will use a conventional 0.05 p-value threshold and expressed optimism about the chances of success, while an Ultragenyx watcher speculated the market was prematurely pricing in study failure.<stembedurl>https://stocktwits.com/RenHenInvestments/message/620415451</stembedurl><stembedurl>https://stocktwits.com/bhavn008/message/620395599</stembedurl>While Ultragenyx’s stock has risen 0.7% so far in 2025, Mereo’s stock&nbsp;has declined 14% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ultragenyx (RARE) and Mereo BioPharma (MREO) slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 as initially planned/ Photo credit: Getty Images

Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdone

Shares of Ultragenyx and Mereo BioPharma slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 (setrusumab) as initially planned, rather than ending it early as they had hoped.

Equity

The companies now expect final data from the Orbit and Cosmic studies by the end of the year.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

RARE
Ultragenyx Pharmaceutical Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RARE News

RARE Ultragenyx Pharmaceutical Inc.